An FDA advisory panel voted against approving Alkermes Plc’s depression treatment ALKS 5461 in patients with an inadequate response to standard antidepressant therapies.

Beleaguered PixarBio Corporation slashed the company’s workforce by half and moved its operations from Massachusetts to New Hampshire. PixarBio revealed its moves in a July 2017 filing with the U.S. Securities and Exchange Commission.

July 21, 2017 By Alex Keown, BioSpace.com Breaking News Staff DUBLIN – Less than one month after Endo International (ENDP) agreed to pull its opioid pain medication, the reformulated Opana ER, from the market, the company announced it was shuttering a manufacturing facility in Alabama and terminating hundreds of employees. Endo said the move follows […]

A U.S. advisory panel recommended approval of Pfizer Inc’s long-acting opioid painkiller Troxyca ER, saying it dulls pain and its design could deter abuse by addicts in search of a quick high.

A U.S. advisory panel recommended approving Teva Pharmaceutical Industries’ long-acting opioid painkiller Vantrela ER, saying data showed it has some abuse-resistant properties.

Titan Pharmaceuticals announced that the U.S. FDA approved Probuphine (buprenorphine) implant for long-term maintenance of opioid dependence.

With a nod to his own drug use as a young man, President Barack Obama on Tuesday called for more funding and a new approach to help people addicted to heroin and prescription drugs, seeking to shine a public spotlight on an increasingly deadly killer. During an appearance at a drug abuse summit in Atlanta, […]

Indivior Plc said on Tuesday the U.S. Food and Drug Administration rejected its nasal spray for the emergency treatment of opioid overdose. The company said it was reviewing the health regulator’s response. These sprays contain naloxone, a drug that has been used to treat opioid overdose for nearly 45 years in injectable forms. Last week, […]

The U.S. Food and Drug Administration approved the first-ever nasal spray emergency treatment for opioid overdose on Wednesday. The spray, developed by privately held Adapt Pharma Ltd, uses naloxone, a drug used to treat opioid overdose for nearly 45 years but approved only in injectable forms. Data from the Centers for Disease Control and Prevention […]

NEWARK, Calif., Nov. 17, 2015 /PRNewswire/ — Depomed, Inc. (NASDAQ: DEPO) today announced that it has entered into a definitive agreement to acquire the U.S. and Canadian rights to cebranopadol and its related follow-on compound from Grünenthal GmbH (“Grünenthal”). Cebranopadol is a novel, first-in-class analgesic in development for the treatment of moderate to severe chronic nociceptive […]